Genetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis Drugs-Reference-Cited by-同舟云学术

Genetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis Drugs

Published:2023-08-28 Issue:4 Volume:101 Page:87-93
ISSN:2542-1506
Container-title:Tuberculosis and Lung Diseases
language:
Short-container-title:Tuberk. bolezni lëgk.

Author:

Kukurika A. V.¹,Veselova E. I.¹,Peregudova A. B.¹

Affiliation:

1. National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health

Abstract

We analyzed 57 publications devoted to study of genetic mechanisms of formation of drug resistance of Mycobacterium tuberculosis to bedaquiline, delamanid, pretomanid, linezolid, and clofazimine. Identification of genetic factors of MTB drug resistance make the basis to search for new targets in development of anti-tuberculosis drugs and methods for drug susceptibility testing.

Publisher

LLC "Medical Knowledge and Technologies"

Subject

General Medicine

Reference57 articles.

1. Vasilyeva I. A., Samoylova A. G., Zimina V. N., Lovacheva O. V., Abramchenko A. V. Chemotherapy for tuberculosis in Russia - the story continues. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 2, pp. 8-12. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-2-8-12

2. Gayda A. I., Abramchenko A. V., Romanova M. I., Toichkina T. V., Burykhin V. S., Borisov S. E., Filippov A. V., Kuznetsova T. A., Perkhin D. V., Sveshnikova O. M., Lekhleyder M. V., Panteleev A. M., Toinova S. V., Maslennikova T. I., Galakhova D. O., Populyashina L. N., Saenko G. I., Anisimova E. S., Svicharskaya A. K., Sosova N. A., Lovacheva O. V., Maryandyshev A. O., Samoylova A. G. Substantiation of duration of chemotherapy in tuberculosis patients with multiple and pre-extensive drug resistance in the Russian Federation. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 12, pp. 44-53. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-12-44-53

3. Almeida D., Ioerger T., Tyagi S., et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2016, no. 60, pp. 4590-9.

4. Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One, 2014, no. 9, pp. e102135.

5. Battaglia S., Spitaleri A., Cabibbe A. M., Meehan C. J., Utpatel C., Ismail N., Tahseen S., Skrahina A., Alikhanova N., Mostofa Kamal S. M., Barbova A., Niemann S., Groenheit R., Dean A. S., Zignol M., Rigouts L., Cirillo D. M. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains // J. Clin. Microbiol. // 2020. - Vol. 58, № 11. - Р. e01304-20.